Drug Trial Radar · NCT00851942
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
Last checked: Nov 20, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Sep 2008
Primary completion
Jul 28, 2012
Study completion Jan 31, 2013
Sponsor
- Lead sponsor
- Cardiff UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Objectives: To establish valid serum total cortisol and salivary cut-offs for use with the short Synacthen test in patients with normal CBG concentrations. To investigate, using current assays, the effect of assay differences on the serum total cortisol cut-off. To explore the performance of these cut-offs in groups of patients with suspected adrenal insufficiency and high and low serum CBG concentration. Methodology: An ACTH test (250 micrograms iv ACTH1-24) will be undertaken in healthy volunteers, women taking an oestrogen-containing oral contraceptive pill (OCP), patients with adrenal insufficiency and patients with low serum albumin. Serum cortisol in the samples collected from healthy volunteers will be measured using GC-MS, Advia Centaur (Siemens), Architect (Abbott), Modular Analytics E170 (Roche), Immulite 2000 (Siemens) and Access (Beckman) automated immunoassays. The estimated lower reference limit for the 30 min cortisol response to ACTH, defined as the 2.5th percentile of log-transformed concentrations, will be determined in this healthy population and used as a cut-off in the patient groups studied.
Conditions
- Healthy
- Adrenal Insufficiency
- Hypopituitarism
Interventions
Synacthen (Tetracosactrin)Drug
IV injection of 250 micrograms of Synacthen in 1ml
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary end-point of the study will be to establish method dependent cortisol cut offs for the normal response to Synacthen® using the 5th percentile.Time frame: Cortisol response at 30 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Facility, University Hospital of Wales
Cardiff, South Glamorgan, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.